Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.

Jeong Heo Yun Joon Kim Jin-Woo Lee Ji Hoon Kim Young Suk Lim Kwang-Hyub Han Sook-Hyang Jeong Mong Cho Ki Tae Yoon Si Hyun Bae Eric D Crown Linda M Fredrick Negar Niki Alami Armen Asatryan Do Hyun Kim Seung-Woon Paik Youn Jae Lee

Published in: Gut and liver (2021)

G/P therapy was highly efficacious and well tolerated in Korean patients with HCV infection, with most patients achieving SVR12. The safety profile was comparable to that observed in a pooled analysis of a global pan-genotypic population of patients with HCV infection who received G/P.

Keyphrases

phase ii
hepatitis c virus
end stage renal disease
clinical trial
ejection fraction
chronic kidney disease
newly diagnosed
open label
human immunodeficiency virus
randomized controlled trial
mesenchymal stem cells
patient reported outcomes
cell therapy